Linde PLC vs McKesson Corporation — how do they compare? Linde PLC trades at $512 (market cap $236.74B), while McKesson Corporation trades at $829.95 (market cap $97.35B). The key difference: Linde PLC is far larger — about 2.4× McKesson Corporation's market cap, and Linde PLC pays the higher dividend (1.25%). Which is the better fit depends on your goals.
| LIN | MCK | |
|---|---|---|
Market Cap | $236.74B | $97.35B |
Sector | Basic Materials | Health |
52-Week High | $546.64 | $995.69 |
52-Week Low | $389.38 | $659.01 |
Enterprise Value | $259.10B | $101.98B |
Dividend Yield | 1.25% | 0.39% |
Signals from Pluang's Aura AI — not financial advice
Linde (LIN) trades at $512.05, down 0.2% on the day, with strong fundamentals including 20.44% net income margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with revenue growth to $34.0B in 2025. Recent Q1 2026 results showed EPS of $4.33 beating estimates, while analyst consensus remains strongly bullish with 89% buy ratings and a $564.80 price target.
LIN presents a compelling long-term investment with premium valuation metrics offset by exceptional profitability and dividend growth. Key risks include elevated debt levels (debt-to-asset ratio rising to 31.63% in 2025) and potential margin pressure from economic cycles. The current technical weakness may offer entry points for investors seeking quality industrial exposure with sustainable growth prospects.
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Trailing returns across standard periods
Latest headlines on both assets
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →